AAUM (Average Assets Under Management) of ₹8,280.57 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 72.4% | 72.5% | ● +0.1% |
| Healthcare Services | 21.9% | 22.0% | ● +0.1% |
| Retailing | 3.7% | 3.2% | ▼ -0.5% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 72.5% | 73.5% | ▲ +1.0% |
| Healthcare Services | 22.0% | 21.1% | ▼ -0.9% |
| Retailing | 3.2% | 2.7% | ▼ -0.5% |
Comparing Jun 2026 → Jul 2026
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Piramal Pharma Limited ₹194.38 Cr |
Pharmaceuticals & Biotechnology | 1.02% | 2.09% | +1.07% |
| 2 | Divi's Laboratories Limited ₹604.81 Cr |
Pharmaceuticals & Biotechnology | 5.46% | 6.52% | +1.06% |
| 3 | Sun Pharmaceutical Industries Limited ₹1,235.37 Cr |
Pharmaceuticals & Biotechnology | 12.78% | 13.31% | +0.53% |
| 4 | Biocon Limited ₹85.31 Cr |
Pharmaceuticals & Biotechnology | 0.68% | 0.92% | +0.24% |
| 5 | Dr. Lal Path Labs Limited ₹190.63 Cr |
Healthcare Services | 1.85% | 2.05% | +0.20% |
| 6 | Sanofi India Limited ₹99.63 Cr |
Pharmaceuticals & Biotechnology | 0.87% | 1.07% | +0.20% |
| 7 | GlaxoSmithKline Pharmaceuticals Limited ₹246.64 Cr |
Pharmaceuticals & Biotechnology | 2.47% | 2.66% | +0.19% |
| 8 | Abbott India Limited ₹207.95 Cr |
Pharmaceuticals & Biotechnology | 2.09% | 2.24% | +0.15% |
| 9 | Sai Life Sciences Limited ₹336.11 Cr |
Pharmaceuticals & Biotechnology | 3.49% | 3.62% | +0.13% |
| 10 | Pfizer Limited ₹153.52 Cr |
Pharmaceuticals & Biotechnology | 1.56% | 1.65% | +0.09% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Dr. Reddy's Laboratories Limited ₹464.95 Cr |
Pharmaceuticals & Biotechnology | 6.68% | 5.01% | -1.67% |
| 2 | MedPlus Health Services Limited ₹249.92 Cr |
Retailing | 3.18% | 2.69% | -0.49% |
| 3 | Vijaya Diagnostic Centre Limited ₹224.73 Cr |
Healthcare Services | 2.80% | 2.42% | -0.38% |
| 4 | Mankind Pharma Limited ₹346.84 Cr |
Pharmaceuticals & Biotechnology | 4.03% | 3.74% | -0.29% |
| 5 | Syngene International Limited ₹135.12 Cr |
Healthcare Services | 1.70% | 1.46% | -0.24% |
| 6 | Aurobindo Pharma Limited ₹142.63 Cr |
Pharmaceuticals & Biotechnology | 1.75% | 1.54% | -0.21% |
| 7 | Lupin Limited ₹672.33 Cr |
Pharmaceuticals & Biotechnology | 7.45% | 7.25% | -0.20% |
| 8 | Max Healthcare Institute Limited ₹291.99 Cr |
Healthcare Services | 3.32% | 3.15% | -0.17% |
| 9 | Thyrocare Technologies Limited ₹232.56 Cr |
Healthcare Services | 2.65% | 2.51% | -0.14% |
| 10 | Cipla Limited ₹559.09 Cr |
Pharmaceuticals & Biotechnology | 6.15% | 6.03% | -0.12% |
35 stocks — Jul 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹1,235.37 Cr |
Pharmaceuticals & Biotechnology |
13.31%
|
|
| 2 |
₹672.33 Cr |
Pharmaceuticals & Biotechnology |
7.25%
|
|
| 3 |
₹604.81 Cr |
Pharmaceuticals & Biotechnology |
6.52%
|
|
| 4 |
₹559.09 Cr |
Pharmaceuticals & Biotechnology |
6.03%
|
|
| 5 |
₹491.56 Cr |
Healthcare Services |
5.30%
|
|
| 6 |
₹464.95 Cr |
Pharmaceuticals & Biotechnology |
5.01%
|
|
| 7 |
₹346.84 Cr |
Pharmaceuticals & Biotechnology |
3.74%
|
|
| 8 |
₹336.11 Cr |
Pharmaceuticals & Biotechnology |
3.62%
|
|
| 9 |
₹316.69 Cr |
Pharmaceuticals & Biotechnology |
3.41%
|
|
| 10 |
₹291.99 Cr |
Healthcare Services |
3.15%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.